Inhalation Sciences gets large order from AstraZeneca

STOCKHOLM, SVERIGE – 27 september, 2017. Inhalation Sciences (ISAB) has received an order for a complete PreciseInhale system, including all its test modules, from AstraZeneca.

ISAB, which recently carried out an oversubscribed share issue ahead of its listing on AktieTorget in Stockholm, develops and sells advanced lab equipment for inhalation R&D that measures how particles in inhaled air affect our health. ISAB has successfully delivered PreciseInhale to a number of other key customers and Key Opinion Leaders, including Chiesi Farmaceutici, Kings College and Dow Chemicals.

AstraZeneca has ordered PreciseInhale and the whole range of its test modules corresponding to an order value of 3.2 MSEK. The system will be delivered in stages, with the order including advanced modules still being refined and developed.

ISAB CEO Fredrik Sjövall: "This is obviously a breakthrough order for us, and we’re delighted to deepen our cooperation with AstraZeneca. We’re still just seeing the beginning of what PreciseInhale can contribute to the pharmaceutical industry. I’m convinced this will grow interest in our products worldwide”

For more information about Inhalation Sciences please contact:

Fredrik Sjövall, CEO 
Email: fredrik.sjovall@inhalation.se
Phone: +46 (0)70 64 508 75

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on September 27, 2017.